Rapid development and deployment of vaccines greatly reduced mortality and morbidity
during the COVID-19 pandemic. The most widely used COVID-19 vaccines approved by …

Optimal vaccines are needed for sustained suppression of SARS‐CoV‐2 and other novel
coronaviruses. Here, we developed a recombinant type 5 adenovirus vector encoding the …

The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much
optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently …

To develop a vaccine candidate against coronavirus disease 2019 (COVID-19), we
generated a lentiviral vector (LV) eliciting neutralizing antibodies against the Spike …

Several vaccines have been introduced to combat the coronavirus infectious disease‐2019
(COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS …

SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …

Introduction The global spread of COVID-19 has prompted the development of vaccines. A
recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by …

The unprecedented coronavirus disease 2019 (COVID-19) is triggered by a novel strain of
coronavirus namely, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) …

Background The ongoing COVID-19 pandemic has resulted in 185 million recorded cases
and over 4 million deaths worldwide. Several COVID-19 vaccines have been approved for …

SARS-CoV-2 vaccination significantly reduces morbidity and mortality, but has less impact
on viral transmission rates, thus aiding viral evolution, and the longevity of vaccine-induced …